Truist Securities Downgrades Agilon Health to Hold, Lowers Price Target to $10
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Jailendra Singh has downgraded Agilon Health (NYSE:AGL) from Buy to Hold and reduced the price target from $23 to $10.
January 05, 2024 | 6:07 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Agilon Health's stock rating was downgraded by Truist Securities from Buy to Hold, with a significant price target cut from $23 to $10.
The downgrade from Buy to Hold suggests that Truist Securities no longer sees the same growth potential or value in Agilon Health as before. The substantial decrease in the price target from $23 to $10 indicates a significant revision of the stock's expected performance, which could lead to a negative investor sentiment and a potential decrease in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100